Headlands Technologies LLC Ascendis Pharma A/S Call Options Transaction History
Headlands Technologies LLC
- $920 Million
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ASND
# of Institutions
226Shares Held
56.6MCall Options Held
138KPut Options Held
249K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.28 Billion20.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.96MShares$628 Million3.41% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.3MShares$544 Million0.93% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.2MShares$531 Million7.81% of portfolio
-
Janus Henderson Group PLC London, X03.92MShares$496 Million0.29% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.06B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...